DMN:FRA
Diamyd Medical AB
0,063 €
arrow_downward
-0,63%(-0,00040) 1D
13 նոյ, 22:00:00 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
139,51 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
139,51 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
BigGo Finance
·
9 ժամ առաջ
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
Benzinga
·
2 ժամ առաջ
Dow Jones, Nasdaq 100, and S&P 500 Outlooks: Key Stock Market News This Week
The Motley Fool
·
4 ժամ առաջ
This Dividend King Yields 5 Times the S&P 500. Is It a Buy Now?
Traders Union
·
6 ժամ առաջ
Chris Ciovacco: Semiconductors SMH and S&P 500 SPY show several possible support areas
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB